Salmonellosis stands as an omnipresent foodborne illness that afflicts individuals around the globe. There are many manifestations of salmonellosis including abdominal cramps, diarrhea, and the sensation of nausea. The transmission of salmonellosis among humans results from the consumption of contaminated sustenance or beverages. There are two types of antigens produced by Salmonella including the Vi antigen which is synthesized by Salmonella typhi, and the O-antigen which is generated by non-typhoidal Salmonella strains. It is shown that Vi antigen comprises O-acetylated α-1,4-linked N-acetylgalactosaminuronic acid residues that conjoin the cellular surface through a lipid structure located at the terminal end. The O-antigen capsule is an important part of the extracellular matrix that works together with cellulose and fimbriae in a coordinated way. These polysaccharide antigens play a pivotal role in the development of Salmonella vaccines and warrant attention in future endeavors.
Fig.1 Transmission and prevention of Salmonella infections. (Perera, et al., 2021)
CD BioGlyco provides simple approaches to produce two kinds of Salmonella polysaccharide antigens: Salmonella lipopolysaccharide (LPS) and capsular polysaccharide (CPS). In the meantime, we characterize these polysaccharide antigens by diverse technologies, including sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), high-performance liquid chromatography-size exclusion chromatography (HPLC-SEC), proton nuclear magnetic resonance (1H NMR), and mass spectrometry (MS) to guarantee product quality.
To reduce the worldwide impact of salmonellosis and related bacteremia, CD BioGlyco utilizes various carriers such as Flagellin and Cross-reacting Material 197 (CRM197) to attach to the Salmonella polysaccharides for the preparation of conjugates. This makes us develop a vaccine that targets frequently encountered Salmonella serovars. Besides, we characterize the conjugate by various technologies.
Fig.2 The characterization technologies of Salmonella polysaccharide antigen. (CD BioGlyco)
In the field of glycoscience, CD BioGlyco is an advanced company that is proud of our remarkable Glyco™ Vaccine Development Platform. We are proficient in the realm of Carbohydrate-based Vaccine Development. With an exceptional research team, we strive to produce various polysaccharide antigens that boost the development of carbohydrate-based vaccines. If our expertise attracts your attention, please don't hesitate to contact us right away to obtain additional in-depth details.
Reference:
